Company AnaptysBio, Inc.

Equities

ANAB

US0327241065

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
22.52 USD +5.33% Intraday chart for AnaptysBio, Inc. -7.89% +5.14%

Business Summary

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Number of employees: 117

Sales per Business

USD in Million2022Weight2023Weight Delta
GSK - Royalty
100.0 %
5 51.4 % 17 100.0 % +224.51%

Sales per region

USD in Million2022Weight2023Weight Delta
United States and Australia
100.0 %
10 100.0 % 17 100.0 % +66.78%

Managers

Managers TitleAgeSince
Chief Executive Officer 44 21-11-25
Director of Finance/CFO 69 20-07-14
Chief Tech/Sci/R&D Officer 49 20-07-30
Investor Relations Contact - -
Corporate Officer/Principal - 22-06-30
Corporate Officer/Principal - 21-12-31
Corporate Officer/Principal - 17-12-31
Human Resources Officer - 19-09-30
Comptroller/Controller/Auditor 52 17-03-31
General Counsel - 18-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 77 15-06-29
Director/Board Member 72 18-03-04
Director/Board Member 65 21-01-17
Director/Board Member 47 21-04-07
Director/Board Member 60 15-06-29
Chairman 59 23-09-14
Director/Board Member 71 17-08-23
Chief Executive Officer 44 21-11-25
Director/Board Member 62 23-04-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 26,763,081 26,656,090 ( 99.60 %) 0 99.60 %

Shareholders

NameEquities%Valuation
EcoR1 Capital, LLC
28.30 %
7,521,024 28.30 % 192 M $
Deep Track Capital LP
7.665 %
2,036,990 7.665 % 52 M $
Tang Capital Management LLC
7.340 %
1,950,609 7.340 % 50 M $
BlackRock Advisors LLC
6.188 %
1,644,362 6.188 % 42 M $
Vanguard Fiduciary Trust Co.
5.193 %
1,380,115 5.193 % 35 M $
Boxer Capital LLC
4.892 %
1,300,000 4.892 % 33 M $
First Light Asset Management LLC
4.655 %
1,237,178 4.655 % 32 M $
Woodline Partners LP
4.497 %
1,194,974 4.497 % 31 M $
976,981 3.676 % 25 M $
Frazier Life Sciences Management LP
3.385 %
899,700 3.385 % 23 M $

Company contact information

AnaptysBio, Inc.

10770 Wateridge Circle Suite 210

92121-5801, San Diego

+858 362 6295

http://www.anaptysbio.com
address AnaptysBio, Inc.(ANAB)